Thesis (M.S.O.T.) PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you. / PURPOSE: Past research has shown discrepancy between parent and child report of health-related outcomes, leading to questions regarding the use of parents as proxy reporters for their children. It is not known whether similar discrepancies exist between child and parent views of the child’s participation following spinal cord injury. It is also unclear how perception of participation in youth after spinal cord injury compares to self-perception of participation for youth without disabilities. The current study investigated these questions. PROCEDURE: A secondary analysis was completed on data collected from children and youth with a spinal cord injury ages 8-21 years (n=381) and their parents using the Shriner’s Participation Scale. The young person’s self-perception ratings of participation were compared to his/her parent’s perception of their participation, and patterns of self-perception of participation among peers without disabilities . ICC’s were conducted to determine levels of consistency among parent-child dyad responses. Responses from a sample of children and youth without disabilities (n=2005) were compared by t-test to those of the youth with a spinal cord injury determine whether there were differences in how often each group reported they are unable to participate in certain activities. SUMMARY OF FINDINGS: Overall low levels of agreement were found between parent and child perceptions of the child’s participation. The highest agreement (average ICC) between parent and child was found in the 14-17 year old age group. There was a significant difference in self-perception of ability to participate in certain activities between the youth with spinal cord injury and their peers without disabilities. / 2031-01-01

The lamprey is a basal vertebrate that achieves spontaneous functional recovery after complete spinal cord transection over a stereotypical period of 12 weeks. Despite anatomical, physiological, and behavioral data on spinal cord regeneration in lamprey, the molecular mechanisms underlying this capacity are largely unknown. In this study, next generation RNA-sequencing (RNA-Seq) of the brain and injury site within the spinal cord was used to determine and compare transcriptional profiles of uninjured and recovered lampreys at 12 weeks after spinal cord injury (SCI), when normal swimming behavior is achieved. The objective of this study was to determine if recovered animals had a significantly different transcriptional program than uninjured animals. Significant differences in gene expression were observed, with 1468 and 1033 differentially expressed genes in the spinal cord and brain respectively. Leveraging functional data for mammalian homologs of differentially expressed genes, several conserved transcription factors and molecular pathways in both uninjured and injured animals were identified. Gene expression patterns associated with functional recovery in lampreys may be useful in guiding studies aimed at modulating mammalian responses to spinal cord injury, and promoting functional recovery in species with less spontaneous regenerative potential. / 2019-07-11T00:00:00Z

Neurotrauma is a general term describing injury to the central nervous system (CNS); which comprises of the brain and spinal cord. The damage resulting from neurotrauma includes primary injury, which occurs from different sources such as compressed air hitting the brain (bTBI) or an object/bone contusing the spinal cord, resulting in a spinal cord injury (SCI). These various means of primary brain and spinal cord injury are further complicated by the many possible combinations of severity levels and frequencies. However, primary injuries are regarded in many cases as unavoidable with the immediate nerve damage being largely irreversible. Despite all this, primary injuries of the CNS are related by common biochemical pathways in secondary injury. Secondary injury is the cause of declining outcomes after neurotrauma and poor recovery. Secondary injury begins immediately after primary injury and can continue to trigger death of neurons for years later. Given this contribution to poor recovery and its slow progression, secondary injury provides an excellent window of opportunity for therapeutic intervention. A major factor and key link in secondary injury and its perpetuation is reactive aldehyde formation, such as acrolein, from lipid peroxidation. The common formation of acrolein in neurotrauma is attributed to the unique structure of the CNS: with neurons containing a high lipid content from myelin and heavy metabolic activity they are vulnerable to acrolein formation. Thus, acrolein in secondary injury is a point of pathogenic convergence between the various forms of neurotrauma, and may play a role as well in the development of neurotrauma linked disorders and related neurodegeneration. The overall goal of this thesis is to therefore develop better strategies for acrolein removal. We explore here endogenous clearance strategies and targeted drug delivery in SCI, investigate detailed cellular structure changes in bTBI, and acrolein formation and removal in Parkinson’s disease. These findings of pathology, and effectiveness of new or existing acrolein removal strategies, will allow us to better employ treatments in future studies.

Part I. Development of an isoxylitone analog as an antiepileptic drug candidate. Delphinium denudatum is a medicinal plant traditionally used to treat a variety of conditions in Central Asia. Its interesting anticonvulsant effects were determined to be a property of the compound isoxylitone. Prior work from our group in collaboration with the Poulter group from Western University investigated this compound and generated a large number of isoxylitone analogs in order to optimize its antiepileptic activity. This led to the discovery of the prodrug 13 and the active form 15 shown below, which emerged as the most potent. In this work, the library of analogs was further expanded with 22 new compounds with several which matched the activity of 13 and 15, such as compounds 22 and 37, which led to valuable new insights on the activity of these analogs, and suggested other possible future improvements. In addition, efforts were continued regarding developing compound 15 as a clinical trial candidate. Optimization of the synthesis was performed to drastically reduce costs and waste of chemicals, as well as accelerating the duration of the synthesis. The purification of the final product was also greatly facilitated by the direct synthesis of 15, compared to the prior process of first preparing 13 and hydrolyzing the ester. Efforts were exerted to gather additional knowledge on the characteristics of the compound, with structural and conformational analysis via X-ray crystallography and NOE NMR as well as accelerated stability studies to test the viability of 15 in long-term storage under various conditions. All the information gathered throughout this work supported 15 and its sodium salt as excellent clinical trial candidates as treatments for epilepsy. Part II. Synthesis of SOX9 inhibitors as promoters of recovery from spinal cord injury. According to the World Health Organization, 250 to 500 thousand people develop a spinal cord injury each year with a large portion resulting in tetraplegia. A common misconception is that this is permanent because the damaged nerves cannot be repaired. In fact, nerves can and do regrow after being damaged, but cannot do so after spinal cord injuries due to formation of scar tissues which physically and chemically prevents the healing. The Brown group at Western University identified the SOX9 transcription factor as an important promoter of the formation of this scar and showed that SOX9 inhibitors could improve recovery and mobility in mice affected by spinal cord injuries. In collaboration with their group, previous work in our lab performed and SAR study on the lead compounds ZO2(1) and STL26 (2), shown below. The different sections of the molecule have been designated units A to D, to simplify discussion. Initial work by our group established an efficient method to prepare a library of analogs of the lead compounds. A number of compounds were prepared, which primarily investigated small amines as unit A and phenols with small aliphatic substituents as unit D. The initial SAR data confirmed the validity of STL26 as lead compound, as most alterations to the structure were detrimental to the SOX9 inhibitory activity. The objective of this work was to build on these preliminary SAR results, and expand the library of analogs. Larger substituents were introduced in unit A and D and showed that any group larger or smaller than diethylamide in unit A was detrimental to the activity, but that there seemed to be ample space to increase the size of the unit D isopropyl group. Analogs investigating unit B showed that adding substituents at most of the positions was detrimental, as well as changing the relative positions of unit A and B to be ortho or para to each other. However, the C4 on ring B seemed to be very tolerant to various electron donating or withdrawing functional groups. During this SAR study, a recurring theme was the awful solubility of the compounds in water, which heavily complicated their administration to mice during the bioassays. While none of the analogs tested proved superior to 2, the knowledge accrued during this work painted a clear path forward on which areas of the structure could be safely altered to improve solubility without negative impacts on SOX9 inhibition. Some additional efforts were put into obtaining an accurate three-dimensional structure of an active STL26 (2) analog, and information on the primary conformation in solution. Achieving these goals required the use of NOE NMR experiments and X-ray crystallography. One conformation was discovered to be strongly favoured as a result of an intramolecular hydrogen bond even in protic solvents. Subsequently, a small number of additional analogs were prepared containing modifications that would strongly favor or hinder the preferred conformation, in order to better understand its role in the inhibitory activity. The presence of this hydrogen bond appeared to be key to the activity of the compounds.

Spinal cord injury (SCI) is a physically and mentally devastating condition for which there is no curative treatment. It involves primary trauma from the impact and secondary damage in the form of biochemical cascades that threaten the integrity of functional tissue. Therapeutic interventions can only prevent secondary damages, given the irreversibility of the primary laceration. Experimental therapies for SCI can aim to promote neuronal growth and/or regeneration, promote neuroplasticity in surviving neurons and networks, and enhance neuroprotection, or the survival of spared neurons. Surgical decompression and hypothermia are neuroprotective strategies that usually precede rehabilitational strategies in SCI. Hyperbaric oxygen (HBO) treatment constitutes another promising therapy that can increase the amount of oxygen dissolved in the blood, and therefore, the amount delivered to tissues. Both pre-clinical and clinical studies have illustrated that HBO therapy can enhance motor recovery and exert neurological improvements after SCI. A plethora of pre-clinical studies have elucidated several aspects of its function in SCI; HBO seems to suppress apoptosis, edema, and inflammation, as well as mitigate oxidizing conditions. It can also promote angiogenesis, enhance nerve conduction, and inhibit neural degeneration. The limited number of clinical studies and the heterogeneity of protocols allow for fewer conclusions on the roles of HBO in human SCI: motor benefits are hinted in several clinical trials, while neuroprotective effects include increases in blood oxygen, and suppression of inflammatory responses. However, the number and variety of pre-clinical studies suggest that HBO can exert additional neuroprotective benefits in human SCI, which remain to be explored in the future.

The failure of axonal regeneration is due to myriad reasons both cell intrinsic and extrinsic. In this thesis, I sought to investigate an intrinsic reason for regeneration failure in the CNS. Specifically, I investigated the role of axonal mitochondria in the axonal response to injury. A viral vector (AAV) containing a mitochondrially targeted fluorescent protein (mitoDsRed) as well as fluorescently tagged LC3 (GFP-LC3), an autophagosomal marker, was injected into primary motor cortex, to label the corticospinal tract (CST), of adult rats. The axons of the CST were then injured by dorsal column lesion at C4-C5. We found that mitochondria in injured CST axons near the injury site are fragmented and fragmentation of mitochondria persists for two weeks before returning to pre-injury lengths. Fragmented mitochondria have consistently been shown to be dysfunctional and detrimental to cellular health. Interestingly, transection of axons within the sciatic nerve resulted in mitochondrial fission but did not result in the fragmentation of mitochondria. Inhibition of Drp1, the GTPase responsible for mitochondrial fission, using a specific pharmacological inhibitor (mDivi-1) blocked fragmentation. Additionally, it was determined that there is increased mitophagy in CST axons following spinal cord injury based on increased colocalization of mitochondria and LC3. In vitro models revealed that mitochondrial calcium uptake is necessary for injury induced mitochondrial fission, as inhibiting mitochondrial calcium uptake using RU360, a mitochondrial calcium uniporter inhibitor, prevented injury induced fission. This phenomenon was also observed in vivo. These studies indicate that following injury, both in vivo and in vitro, axonal mitochondria undergo increased fission, which may result in an ATP deficit that contributes to the lack of regeneration seen in CNS neurons. / Biomedical Sciences

An increased prevalence and earlier onset of cardiovascular disease (CVD) occurs in persons with spinal cord injury (SCI); the higher risk may be explained by novel CVD risk factors of aerobic capacity and peripheral vascular structure and function. Physical inactivity likely contributes to the basis of increased CVD risk after SCI, however evidence on the effectiveness of exercise programs in attenuating CVD risk in SCI is insufficient. The present thesis evaluated novel CVD risk factors in a cohort of individuals with chronic SCI, and examined the effects of a single bout of exercise and exercise training on CVD risk. The first study demonstrated dramatic decreases in body composition, aerobic capacity, and sublesional endothelial function via flow-mediated dilation (FMD) in adults with chronic SCI vs. able-bodied (AB) controls. The second, third, and fourth studies assessed the role of shear rate (SR) patterns on FMD. Elevated retrograde SR had a detrimental effect on brachial and superficial-femoral-artery (SFA) FMD in both SCI and AB, but elevated anterograde SR had a favorable effect on SFA FMD in AB only. The fifth study demonstrated that sublesional vasculature does not respond to a 4-month combination aerobic and resistance-training program using the recently released physical activity guidelines for adults with SCI (PAG). The results of this thesis highlight the multilayered regulation of sublesional vasculature, and that it may respond differently to a single bout of exercise and exercise training when compared to an AB population. This information is crucial when designing strategies to combat impaired vascular structure and function after SCI. The results from this thesis also indicate the potential for the PAG to improve aspects of anthropometrics, body composition, and carotid vascular health in adults with SCI. Further investigations are necessary to delineate the effects of SCI itself, and of exercise, on CVD risk in this population. / Dissertation / Doctor of Science (PhD)

No description available.

Patients with acute spinal cord injury (SCI) have a high risk of venous thromboembolism (VTE) despite receiving thromboprophylaxis. The current standard of care recommended by guidelines is to use low-molecular-weight heparin (LMWH) for thromboprophylaxis for 90 days. This entails once- or twice-daily subcutaneous injections of LMWH for this duration, which is inconvenient for the patients and only partially effective. There are uncertainties about risk factors and the true incidence of SCI-associated VTE, the optimal time to commence thromboprophylaxis, and the optimal duration of thromboprophylaxis. Furthermore, there are currently no studies on the use of direct oral anticoagulants (DOACs) for thromboprophylaxis in patients with SCI. The use of DOACs for prophylaxis in this group can eliminate the inconvenience associated with daily subcutaneous injections for 3 months. To examine the incidence and risk factors of SCI-associated VTE, we performed a retrospective chart review of consecutive adult patients with acute SCI admitted to Hamilton General hospital from 2009 to 2015. The incidence of symptomatic VTE despite the use of thromboprophylaxis was 11% within 90 days of acute SCI; age and presence of other sites of injuries (such as lower limb fractures or pelvic fractures) along with SCI were independent risk factors for symptomatic VTE. To determine the opinion of Canadian spine surgeons about the optimal timing of starting LMWH after acute SCI, a short 5-question electronic survey was sent to the Canadian Spine Society. Data from our survey showed that the understanding about thromboprophylaxis after acute SCI was variable and that most spine surgeons were comfortable with starting LMWH after consultation with the surgeon. Future studies should focus on educational strategies to improve the knowledge base in this area. We will perform a pilot study at the Hamilton General Hospital comparing apixaban versus LMWH for thromboprophylaxis in patients with acute SCI. The use of apixaban for this indication can contribute to cost savings for the healthcare system and increased convenience for the patient. The protocol for the pilot study as well as steps towards a multi-center randomized controlled trial will be detailed in this thesis. / Thesis / Master of Science (MSc)

Part I. Development of an isoxylitone analog as an antiepileptic drug candidate. Delphinium denudatum is a medicinal plant traditionally used to treat a variety of conditions in Central Asia. Its interesting anticonvulsant effects were determined to be a property of the compound isoxylitone. Prior work from our group in collaboration with the Poulter group from Western University investigated this compound and generated a large number of isoxylitone analogs in order to optimize its antiepileptic activity. This led to the discovery of the prodrug 13 and the active form 15 shown below, which emerged as the most potent. In this work, the library of analogs was further expanded with 22 new compounds with several which matched the activity of 13 and 15, such as compounds 22 and 37, which led to valuable new insights on the activity of these analogs, and suggested other possible future improvements. In addition, efforts were continued regarding developing compound 15 as a clinical trial candidate. Optimization of the synthesis was performed to drastically reduce costs and waste of chemicals, as well as accelerating the duration of the synthesis. The purification of the final product was also greatly facilitated by the direct synthesis of 15, compared to the prior process of first preparing 13 and hydrolyzing the ester. Efforts were exerted to gather additional knowledge on the characteristics of the compound, with structural and conformational analysis via X-ray crystallography and NOE NMR as well as accelerated stability studies to test the viability of 15 in long-term storage under various conditions. All the information gathered throughout this work supported 15 and its sodium salt as excellent clinical trial candidates as treatments for epilepsy. Part II. Synthesis of SOX9 inhibitors as promoters of recovery from spinal cord injury. According to the World Health Organization, 250 to 500 thousand people develop a spinal cord injury each year with a large portion resulting in tetraplegia. A common misconception is that this is permanent because the damaged nerves cannot be repaired. In fact, nerves can and do regrow after being damaged, but cannot do so after spinal cord injuries due to formation of scar tissues which physically and chemically prevents the healing. The Brown group at Western University identified the SOX9 transcription factor as an important promoter of the formation of this scar and showed that SOX9 inhibitors could improve recovery and mobility in mice affected by spinal cord injuries. In collaboration with their group, previous work in our lab performed and SAR study on the lead compounds ZO2(1) and STL26 (2), shown below. The different sections of the molecule have been designated units A to D, to simplify discussion. Initial work by our group established an efficient method to prepare a library of analogs of the lead compounds. A number of compounds were prepared, which primarily investigated small amines as unit A and phenols with small aliphatic substituents as unit D. The initial SAR data confirmed the validity of STL26 as lead compound, as most alterations to the structure were detrimental to the SOX9 inhibitory activity. The objective of this work was to build on these preliminary SAR results, and expand the library of analogs. Larger substituents were introduced in unit A and D and showed that any group larger or smaller than diethylamide in unit A was detrimental to the activity, but that there seemed to be ample space to increase the size of the unit D isopropyl group. Analogs investigating unit B showed that adding substituents at most of the positions was detrimental, as well as changing the relative positions of unit A and B to be ortho or para to each other. However, the C4 on ring B seemed to be very tolerant to various electron donating or withdrawing functional groups. During this SAR study, a recurring theme was the awful solubility of the compounds in water, which heavily complicated their administration to mice during the bioassays. While none of the analogs tested proved superior to 2, the knowledge accrued during this work painted a clear path forward on which areas of the structure could be safely altered to improve solubility without negative impacts on SOX9 inhibition. Some additional efforts were put into obtaining an accurate three-dimensional structure of an active STL26 (2) analog, and information on the primary conformation in solution. Achieving these goals required the use of NOE NMR experiments and X-ray crystallography. One conformation was discovered to be strongly favoured as a result of an intramolecular hydrogen bond even in protic solvents. Subsequently, a small number of additional analogs were prepared containing modifications that would strongly favor or hinder the preferred conformation, in order to better understand its role in the inhibitory activity. The presence of this hydrogen bond appeared to be key to the activity of the compounds.